2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-165154
    Cyclamidomycin 35663-85-5 98%
    Cyclamidomycin (Desdanine) is an acrylamide antibiotic with antibacterial activity. Cyclamidomycin inhibits nucleoside diphosphate kinase and pyruvate kinase (in E. coli) and oxidative phosphorylation in rat liver mitochondria. Cyclamidomycin is active against S. aureus, M. flavus, S. lutea, B. subtilis, E. coli, S. flexneri, S. typhosa, P. vulgaris, and K. pneumoniae (MICs=3.12-25 mg/ml).
    Cyclamidomycin
  • HY-165155
    CysLT1 receptor antagonist-1 119515-00-3 98%
    CysLT1 receptor antagonist-1 (Compound 4) is an antagonist for cysteinyl leukotriene receptor 1 (CysLT1R) with an IC50 of 3.9 μM. CysLT1 receptor antagonist-1 exhibits weak agonist activity against G-protein-coupled bile acid receptor 1 (GPBAR1) with an efficact of 23% at 10 μM. CysLT1 receptor antagonist-1 can be used for asthma and allergic diseases researchs.
    CysLT1 receptor antagonist-1
  • HY-165362
    AO-1535 87178-48-1 98%
    AO-1535 is a semisynthetic monoglycosylceramide that inhibits the production of reactive oxygen intermediates in human monocytes and macrophages stimulated by phorbol ester and chemotactic tetrapeptide. AO-1535 can be used for the research of inflammatory dermatoses.
    AO-1535
  • HY-165537
    Siphonaxanthin 28526-44-5 98%
    Siphonaxanthin is a keto-carotenoid with anti-angiogenic and anti-inflammatory activity, which is found in green algae. Siphonaxanthin upregulates the expression of death receptor 5 (DR5), induces cancer cell apoptosis, decreases the expression of Bcl-2, and activates caspase-3. Siphonaxanthin is also an inhibitor of FGFR-1. Siphonaxanthin inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), as well as the outgrowth of microvessels in the rat aortic ring. Siphonaxanthin is promising for research of diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis.
    Siphonaxanthin
  • HY-165603
    Si5-N14 3006860-57-4 98%
    Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases.
    Si5-N14
  • HY-167628
    Metamizole hemimagnesium 6150-97-6 98%
    Metamizole (Dipyrone) hemimagnesium is an anti-inflammatory and antioxidant agent with the property of reducing body temperature. Metamizole hemimagnesium can decrease the levels of C-reactive protein (CRP) and interleukin 6 (IL-6). It is also an orally active cyclooxygenase (COX) inhibitor. Metamizole hemimagnesium can inhibit cell proliferation and promote apoptosis. It can be used in the research of inflammation and fever.
    Metamizole hemimagnesium
  • HY-167630
    Ketoprofen sodium 57495-14-4 98%
    Ketoprofen (RP-19583) sodium is a non-steroidal anti-inflammatory agent. Ketoprofen sodium can inhibit the activity of Cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). Ketoprofen is potential in the research of inflammation, immunology, and metabolic disease such as obesity.
    Ketoprofen sodium
  • HY-167643
    Hydroxy tipelukast 1027597-04-1 98%
    Hydroxy tipelukast (Compound MN-002), the metabolite of Compound MN-001, is an orally active phenoxyalkylcarboxylic acid. Hydroxy tipelukast inhibits liver steatosis, lobular inflammation, hepatic ballooning, and hepatic scarring, and reduces liver hydroxyproline levels. Hydroxy tipelukast is promising for research of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Hydroxy tipelukast
  • HY-16764A
    Acorafloxacin hydrochloride 1001162-01-1 98%
    Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Acorafloxacin hydrochloride (Avarofloxacin ) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Acorafloxacin hydrochloride (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
    Acorafloxacin hydrochloride
  • HY-167679
    Scio-323 309913-51-7 98%
    Scio-323 is an orally available p38 mitogen-activated protein kinase (MAPK) inhibitor with the potential to inhibit chronic inflammatory responses associated with polyethylene particles. Scio-323's oral inhibition pattern had a minimal effect on bone formation. Scio-323 administration inhibited net bone formation after the establishment of a chronic inflammatory response to polyethylene particles. Osteoblast-like activity remained low in all cases of Scio-323 inhibition. Scio-323 failed to improve bone growth in the presence of polyethylene particles.
    Scio-323
  • HY-167685
    (E/Z)-Aureusidin 480-70-6 98%
    (E/Z)-Aureusidin is a flavonoid compound with antioxidant activity. (E/Z)-Aureusidin can inhibit the production of reactive oxygen species and reduce cell damage. (E/Z)-Aureusidin has anti-inflammatory effects and can reduce the expression of inflammatory factors. (E/Z)-Aureusidin has inhibitory effects on a variety of bacteria, indicating its potential antimicrobial properties.
    (E/Z)-Aureusidin
  • HY-167706
    Diethyl-Lodoxamide 53882-13-6 98%
    Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design.
    Diethyl-Lodoxamide
  • HY-167884
    PF-1367550 319461-60-4 98%
    PF-1367550 is a pan-JAK inhibitor. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells.
    PF-1367550
  • HY-168211
    LQ-38 98%
    LQ-38 is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 5.2 nM. LQ-38 exhibits anti-inflammatory activity in rat foot edema model and mouse acute pancreatitis model, exhibits analgesic effect in Acetic acid (HY-Y0319)-induced writhing mouse model.
    LQ-38
  • HY-168360
    Bufotenidine iodide 5787-02-0 98%
    Bufotenidine iodide is a component found in toad venom and belongs to the indole alkaloid class.
    Bufotenidine iodide
  • HY-168361
    8β-Hydroxy-exo-THC 52522-55-1 98%
    8β-Hydroxy-exo-THC is a cannabinoid ether analogue with a weaker affinity for receptor sites, with an IC50 of 1.2 μM.
    8β-Hydroxy-exo-THC
  • HY-168369
    Anti-inflammatory agent 94 501927-29-3 98%
    Anti-inflammatory agent 94 (compound 4b) is a potent cannabinoid ligand with Kis of 29 nM and 8 nM against CB2 and CB1. Anti-inflammatory agent 94 can be utilized in inflammation rersearch.
    Anti-inflammatory agent 94
  • HY-168370
    YHS-12 2959463-68-2 98%
    YHS-12 is an ionizable cationic lipid, which can be used to synthesize lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA.
    YHS-12
  • HY-168383
    (E/Z)-Resomelagon acetate 959850-74-9 98%
    (E/Z)-Resomelagon acetate is an agonist of melanocortin receptor 1 (MC1R) and MC3R with anti-inflammatory activities. (E/Z)-Resomelagon can be utilized in inflammation research.
    (E/Z)-Resomelagon acetate
  • HY-168384
    M04 875158-73-9 98%
    M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases.
    M04
Cat. No. Product Name / Synonyms Application Reactivity